Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Mar 11;11(3):e4225.
doi: 10.7759/cureus.4225.

Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy

Scott Zashin  1
Affiliations
Case Reports

Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy

Scott Zashin. Cureus. .

Abstract

Sjogren's Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. In addition, fatigue and musculoskeletal pain, often described as aching, is very common. Treatment directed toward alleviating the fatigue and pain associated with Sjogren's is currently very limited. This report describes a case of a 47-year-old female with suspected Sjogren's based on long-standing dry eyes, dry mouth, joint pain, fatigue, elevated measures of inflammation, and a positive rheumatoid factor. She failed standard therapy but improved clinically with low-dose naltrexone therapy.

Keywords: autoimmune diseases; fatigue; joint pain; low dose naltrexone; sjogren syndrome.

PubMed Disclaimer

Conflict of interest statement

I prescribe low dose naltrexone to patients in my medical practice

References

    1. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Younger J, Mackey S. Pain Med. 2009;10:663–672. - PMC - PubMed
    1. Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. Wang D, Sun X, Sadee W. J Pharmacol Exp Ther. 2007;321:544–552. - PubMed
    1. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Younger J, Parkitny L, McLain D. Clin Rheumatol. 2014;33:451–459. - PMC - PubMed
    1. Glia as the 'bad guys": implications for improving clinical pain control and the clinical utility of opioids. Watkins LR, Hutchinson MF, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Brain Behav Immun. 2007;21:131–146. - PMC - PubMed
    1. Low-dose naltrexone therapy improves active Crohn's disease. Smith JP, Stock H, Bigaman S, Mauger D, Rogosnitzky M, Zagon I. https://insights.ovid.com/pubmed?=17222320. Am J Gastroenterol. 2007;102:820–828. - PubMed

Publication types

LinkOut - more resources